209 related articles for article (PubMed ID: 23032746)
1. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
Kaye SB; Fehrenbacher L; Holloway R; Amit A; Karlan B; Slomovitz B; Sabbatini P; Fu L; Yauch RL; Chang I; Reddy JC
Clin Cancer Res; 2012 Dec; 18(23):6509-18. PubMed ID: 23032746
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
[TBL] [Abstract][Full Text] [Related]
3. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
9. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Konstantinopoulos PA; Brady WE; Farley J; Armstrong A; Uyar DS; Gershenson DM
Gynecol Oncol; 2018 Jul; 150(1):9-13. PubMed ID: 29739622
[TBL] [Abstract][Full Text] [Related]
14. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
[TBL] [Abstract][Full Text] [Related]
16. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
18. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
Dirix L; Rutten A
Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
